

LANKA 202.

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine 231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Vol. 49 No. 20

14th- 20th May 2022

Monkey pox – the emerging epidemic Part

This is the first of a series of 2 articles.

The History of Monkeypox

Monkeypox is a zoonotic disease that is caused by infection with an enveloped double-stranded DNA virus belonging to the group of viruses (Orthopoxvirus genus in the family Poxviridae) which also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus¹. ²With the eradication of smallpox in 1980 and the subsequent cessation of smallpox vaccination, monkeypox has emerged as the most important orthopoxvirus for public health. Monkeypox primarily occurs in central and west Africa, often in proximity to tropical rainforests, and has been increasingly appearing in urban areas. Animal hosts include a range of rodents and non-human primates².

Monkeypox was first identified in Denmark among laboratory cynomolgus monkeys in 1958 when two outbreaks of a smallpoxlike disease occurred in colonies of monkeys captured in Malaysia, and transported via Singapore³. An outbreak of monkeypox at Rotterdam Zoo was reported in 1964⁴. Subsequently, monkeypox was detected in several laboratory monkeys in the US. No further cases in laboratory monkeys occurred after 1968.

The first documented case in humans was in 1970, in an unvaccinated 9-month old boy in the Équateur Province Democratic Republic of the Congo (formerly Zaire) where smallpox had been eliminated in 1968⁵. Almost 50 cases were reported between 1970 and 1979, with more than twothirds of these being from Zaire.

Monkey pox eruption in an African child.



⁵Since 1970, human cases of monkeypox have been reported in 11 African countries: Benin, Cameroon, the Central African Republic, the Democratic Republic of the Congo, Gabon, Cote d'Ivoire, Liberia, Nigeria, the Republic of the Congo, Sierra Leone and South Sudan⁶. The true burden of monkeypox is not known. For example, in 1996-97, an outbreak was reported in the Democratic Republic of the Congo with a lower case fatality ratio and a higher attack rate than usual. ²By 1986, over 400 cases in humans were reported. Small viral outbreaks with a death rate in the range of 10% and a secondary human-to-human infection rate of about the same amount occur routinely in equatorial Central and West Africa⁷. The United States of America experienced an outbreak of Monkeypox in 2003 with 71 laboratory-confirmed cases of monkeypox. Since 2017, Nigeria has ex-

ContentsPage1. Monkey pox – the emerging epidemic Part I12. Summary of selected notifiable diseases reported (07th – 14th May 2022)33. Surveillance of vaccine preventable diseases & AFP (07th – 14th May 2022)4

WER Sri Lanka - Vol. 49 No. 20

perienced a large outbreak, with over 500 suspected cases and over 200 confirmed cases and a case fatality ratio of approximately 3%. Cases continue to be reported until today.

Monkeypox cases in people have occurred outside of Africa linked to international travel or imported animals, including cases in the United States, as well as Israel, Singapore, and the United Kingdom. Monkeypox is a disease of global public health importance as it not only affects countries in west and central Africa but the rest of the world. In 2003, the first monkeypox outbreak outside of Africa was in the United States of America and was linked to contact with infected pet prairie dogs. These pets had been housed with Gambian pouched rats and dormice that had been imported into the country from Ghana. This outbreak led to over 70 cases of monkeypox in the U.S².

Monkeypox has also been reported in travellers from Nigeria to Israel in September 2018, to the United Kingdom in September 2018, December 2019, May 2021 and May 2022, to Singapore in May 2019, and to the United States of America in July and November 2021. In May 2022, multiple cases of monkeypox were identified in several non-endemic countries including Canada, the United States of America, the United Arab Emirates, Australia and many European countries including Spain, Portugal and the United Kingdom². There are currently no known cases in Sri Lanka.

Transmission

The primary transmission of this zoonotic virus (from animal to human) is thought to occur through direct contact with infected animals (while capturing, slaughtering and/or preparing animals for food) or by ingestion of inadequately cooked flesh. If the skin or mucosa is damaged inoculation of the virus may occur. Secondary (human-human) transmission has been known to occur and has been confirmed as a major factor in the current outbreak (2022). Respiratory droplets and direct contact with mucosal/ cutaneous lesions or fomites are postulated as the routes of human-human transmission. However, although many of those affected in the current outbreak are homosexual males, the sexual transmission of monkeypox has not been yet confirmed.

The incidence of monkeypox infection has neither gender predisposition nor racial preference. However, in the African epidemics, 90% of those affected have been <15 years old. In the recent outbreaks, a rising trend of increased incidence among the 15-30-year-old cohort has been seen. Those not vaccinated for smallpox are postulated to be at high risk to contract monkeypox.

There are two distinct genetic clades of the monkeypox virus: the central African (Congo Basin) clade and the west African clade⁹. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible¹⁰. Mortality rates 0f 1%-10% are therefore seen in Africa, although no fatalities occurred in the outbreak in the United States in 2003. The prognosis is influenced by the health and nutrition status,

vaccination status, comorbidities, amount of exposure to the virus, host immune response and the severity of complications.

Compiled By:

Dr. T. D. Bandara

MBBS (Colombo) MSc. Community Medicine

Medical Officer - Epidemiology Unit

District	MOH areas	No: Expected *	No: Received
Colombo	15	90	NR
Gampaha	15	90	NR
Kalutara	12	72	NR
Kalutara NIHS	2	12	NR
Kandy	23	138	NR
Matale	13	78	NR
Nuwara Eliya	13	78	NR
Galle	20	120	NR
Matara	17	102	NR
Hambantota	12	72	8
Jaffna	12	72	NR
Kilinochchi	4	24	NR
Manner	5	30	3
Vavuniya	4	24	NR
Mullatvu	5	30	NR
Batticaloa	14	84	NR
Ampara	7	42	NR
Trincomalee	11	66	NR
Kurunegala	29	174	NR
Puttalam	13	78	NR
Anuradhapura	19	114	NR
Polonnaruwa	7	42	0
Badulla	16	96	NR
Moneragala	11	66	NR
Rathnapura	18	108	NR
Kegalle	11	66	0
Kalmunai	13	78	NR

WER Sri Lanka - Vol. 49 No . 20

14th - 20th May 2022

Tab	ole 1	l: Se	elec	ted	noti	fiab	le d	isea	ases	s rep	orte	ed b	y M	edic	al C	Offic	ers	of H	leal	th	07	7th- •	13 th	Мау	/ 202	22 ('	19 th	We	ek)	
	**S	66	71	100	96	100	100	100	100	100	88	100	81	76	100	100	100	92	66	92	91	88	100	100	95	100	100	95		eteness
WRCI	ř.	10	ŋ	m	∞	17	12	σ	15	24	56	32	22	7	24	32	σ	18	2	13	2	13	σ	9	10	9	26	14		Comple
hmania-	B	1	2	0	4	145	0	0	185	116	0	H	0	4		1	11	0	199	4	194	160	10	64	91	11	0	1206		ek: 335 C** -
Leis	۲	0	0	0	0	0	0	0	m	m	0	0	0	0	0	0	m	0	9	0	Ь	13	m	ω	0	0	0	39		urrent we
ingitis	8	Μ	~	12	2			б	ъ	ъ	4	0	15	0	0	18	∞	m	16	11	17	7	7	16	17	15	13	207		ded for the c
Men	◄	0	0	2	0	0		0	0		0	0	0	0	0		0	0	2			0	0	0		0	0	10		ata provic
kenpox	8	12	11	25	23	8	10	26	14	14	57	m	m	ъ	4	9	27	13	31	ы	21	ы	22	28	32	38	18	461		rting units di
Chic	◄	0		0		0		0	0	0		0	0	0				2		7	0	0	0	ω	2	2	0	19		er of repo
u	8	0		2	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	œ		31 Numbe
Hum	۷	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-		g units 3(
Hep-	8	7	m		S		0	2	m		4	0		0	0			4	0	0	2		52	22	Ξ	2	0	11		of reportin
Viral	۷	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0		4	2	0	0	0	œ		number c
SUC	8	0	0	2	11	2	∞	∞	16	ъ	364	∞	7	Η	4	0		m	15	m	14	0	21	11	8	7		515		2022 Total
Tvph	◄	0	0	0	0	0	0	0	0	0	6		0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	14		3 th May ,
spirosis	8	40	39	118	32	25	20	153	63	99	18	9	11	10	17	15	37	13	40	7	85	46	96	142	279	166	8	1552		on or before 1
Lepto	4	ч	0	ഹ	4			10	0	2	0	m	0	0	4	0	0	m	4	0	0	0	ъ	11	13	ъ		73		received
d Poi-	8	ъ	9	9	4	0	0	0	0	0	19	13	0	0	m	17	2	2	H	0	ъ	H	ъ	2	16	4	4	120		rs to returns
Foo	◄	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	~	0	0	0	0	0	0	0	0	0	0	~		ness refe
ric Fever	В	0	0		0	0	0	0	0	0	38	0	0	2	2	0	0		0	0		0	0	4	2		0	52). T=Timeli
Ente	۷	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		id.gov.lk
phaliti	ш	7	0		0	0	0	0	0	0	2	0	0		0	ы		0		0	0	0	0	0	ы	2	0	20		lance.ep
Ence	۲	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	•		(esurvi
entery	8	2	4	4	2	0	б	m	23	9	14	4		0	ω	41	9	20	9	2	∞	m	9	ഹ	21	ъ	20	223		Diseases
, Dys	۲	0	0	0	m	0	0	0	0	0	2	0	0	0		0	0	0	0	0	0	0		0	0	0		∞		iicable
iue Fever	8	2879	2299	1163	777	184	69	1091	343	390	1506	61	147	4	30	600	63	736	1116	926	160	48	399	134	858	571	370	16964		of Commur
Denc	۷	11	64	73	61	15	∞	83	24	18	97	m		0	0	64	7	50	19	21	4	0	m	∞	38	45	29	84		Returns
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapur	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA		Source: Weekly

Page 3

WER Sri Lanka - Vol. 48 No. 20

Table 2: Vaccine-Preventable Diseases & AFP

07th - 13th May 2022 (19th Week)

14th - 20th May 2022

Disease		N	lo. of	Case	es by	y Pro	ovino	Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date			
	w	С	S	N	Е	NW	NC	U	Sab	week in 2022	week in 2021	2022	2021	in 2022 & 2021	
AFP*	00	00	00	00	00	01	00	00	00	01	01	33	20	65 %	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	00	00	00	00	00	00	00	01	00	01	03	16	41	- 60.9 %	
Measles	00	00	00	00	00	00	00	00	00	00	00	11	08	37.5 %	
Rubella	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Tetanus	00	00	00	00	00	00	00	00	01	01	00	05	02	150 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %	
Tuberculosis	00	00	00	00	00	00	25	00	10	35	117	2564	2377	7.8 %	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

NA = Not Available

Influenza Surveillance in Sentinel Hospitals - ILI & SARI													
Month	Human		Animal										
	No Total	No Positive	Infl A	Infl B	Pooled samples	Serum Samples	Positives						
May													
Source: Medical Research Institute & Veterinary Research Institute													

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. Samitha Ginige Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10